New research, guidelines and FDA decisions, each with a note on what it might change in a conversation with your surgeon, how certain it is, and links to the original sources.
How we choose news. Nothing here is sponsored. Mentioning a product isn't an endorsement, and an FDA clearance means a device was found substantially equivalent to existing ones, not proven better. Updated November 2026.
Research
When is BMP-2 worth its cost in spine fusion?
A 2026 cost analysis of lumbar fusion found BMP-2 was cost-effective only when the baseline risk of a failed fusion was high, and not at low baseline risk regardless of product cost.
What this could change in a conversation with your surgeon: If BMP-2 is planned, ask why your risk of a failed fusion is high enough to justify it.
Stem cell injections for knee arthritis: symptom relief, not new cartilage
A 2026 review of 28 randomized trials of cell-based injections for knee arthritis found improvements in pain and function, but concluded they mainly ease symptoms rather than rebuild joint structure, with more local reactions.
What this could change in a conversation with your surgeon: If you're quoted a price for a stem cell injection, remember the FDA hasn't approved any for orthopedic conditions.